Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYNK-001 in Adults with AML
NCT04310592Phase 1Terminated
- Sponsor
- Celularity Inc.
- Start
- Mar 2020
- Primary completion
- Jan 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CYNK-001 in acute myeloid leukemia (AML) (2 arms), sponsored by Celularity Inc. Primary endpoints: Dose-limiting Toxicity at 28 days, Maximum Tolerated Dose or Maximum Planned Dose at 28 days and 1 more. Started Mar 2020; status: terminated.
02
Drugs
CYNK-001
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04310592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04310592.